Related Experiment Videos

Epidemiology of clinical hyperbilirubinaemia in Al Ain, United Arab Emirates

A Dawodu1, M M Qureshi, I A Moustafa

  • 1Department of Paediatrics, Faculty of Medicine & Health Sciences, Al Ain, United Arab Emirates University, United Arab Emirates.

Annals of Tropical Paediatrics
|January 30, 1999
PubMed

Insights

This study investigated hyperbilirubinemia in newborns at Al Ain Hospital. Key causes included prematurity, ABO hemolytic disease, and G6PD deficiency, with ethnic variations noted.

Area of Science:

  • Neonatal Medicine
  • Pediatrics
  • Public Health

Background:

  • Hyperbilirubinemia (jaundice) is a common neonatal condition requiring medical attention.
  • Understanding the specific causes and risk factors in diverse populations is crucial for effective management.
  • Previous epidemiological data on neonatal hyperbilirubinemia in the United Arab Emirates was limited.

Purpose of the Study:

  • To determine the incidence and etiological factors of clinically significant hyperbilirubinemia in newborns at Al Ain Hospital.
  • To identify potential ethnic variations in the causes of neonatal jaundice.
  • To inform local healthcare strategies for reducing hyperbilirubinemia incidence.

Main Methods:

  • Prospective study of all infants born at Al Ain Hospital between January 1 and June 30, 1995.
  • Inclusion criteria: clinically relevant hyperbilirubinemia requiring investigation and treatment.
  • Data collection on infant demographics, maternal factors, and diagnosed causes of jaundice.

Main Results:

  • A total of 2300 live births, with 85 infants (3.7%) developing hyperbilirubinemia.
  • Prematurity and ABO hemolytic disease were the most frequent causes (22 cases each).
  • Other identified causes included G6PD deficiency (8), breast-milk jaundice (7), maternal diabetes (5), and Rh incompatibility (1).
  • No specific cause was found in 20% of cases.
  • Significant differences in etiological categories were observed across major ethnic groups.

Conclusions:

  • This study provides the first epidemiological data on clinically relevant hyperbilirubinemia in this UAE community.
  • Locally relevant risk factors, including ethnic predispositions, were identified.
  • Targeted interventions addressing identified risk factors could potentially decrease the incidence of neonatal hyperbilirubinemia.

Keywords:
Age FactorsArab CountriesAsiaBilirubinemiaBiologyDemographic FactorsDeveloping CountriesDiseasesEpidemiologyHealthHemic SystemInfantJaundiceNeurologic EffectsPhysiologyPopulationPopulation CharacteristicsPublic HealthResearch ReportSigns And SymptomsUnited Arab EmiratesWestern AsiaYouth

Related Concept Videos

Jaundice01:25

Jaundice

Jaundice, or icterus, is the yellow discoloration of the skin, sclerae, and mucous membranes. It happens when plasma bilirubin levels rise above 2.5-3 mg/dL, leading to bilirubin deposition in tissue.Bilirubin is a byproduct of hemoglobin degradation. In macrophages, hemoglobin breaks down into globin and heme. Globin is converted into amino acids, while heme is turned into biliverdin by heme oxygenase, which is then reduced to unconjugated bilirubin by biliverdin reductase.Unconjugated...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...